NXTCL — NextCell Pharma AB Balance Sheet
0.000.00%
Last trade - 00:00- SEK144.37m
- SEK118.33m
- SEK13.70m
Annual balance sheet for NextCell Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 139 | 97.1 | 50 | 46.8 | 26 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.7 | 2.71 | 3.58 | 3.12 | 5.47 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 146 | 107 | 67.3 | 60.6 | 41.4 |
| Net Property, Plant And Equipment | 2.9 | 9.9 | 13.6 | 12.7 | 14.3 |
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 156 | 125 | 88.8 | 81.3 | 63.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.96 | 6.93 | 10.1 | 9.87 | 8.03 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.53 | 9.12 | 13.1 | 13.7 | 13.3 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 150 | 116 | 75.7 | 67.6 | 50.6 |
| Total Liabilities & Shareholders' Equity | 156 | 125 | 88.8 | 81.3 | 63.9 |
| Total Common Shares Outstanding |